Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GREGORY B HAMMER

Allopathic & Osteopathic Physicians Anesthesiology

NPI
1396885455
CMS profile
944088
Location
STANFORD, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$1,777.27

8 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,140.19 3
Consulting Fee $350.00 1
Food and Beverage $287.08 4

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme Corporation $1,427.27 7
BAXTER HEALTHCARE $350.00 1

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GREGORY B HAMMER

NPI 1396885455 · CMS profile ID 944088

Allopathic & Osteopathic Physicians / Anesthesiology

STANFORD, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1396885455?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GREGORY B HAMMER, NPI 1396885455, CMS profile ID 944088. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396885455?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). GREGORY B HAMMER, NPI 1396885455, CMS profile ID 944088. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396885455?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
GREGORY B HAMMER, NPI 1396885455, CMS profile ID 944088, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1396885455?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

8 matching records · $1,777.27 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 8 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–8 of 8.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
BAXTER HEALTHCARE $350.0007/18/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 629135435 CMS
Merck Sharp & Dohme Corporation $34.9906/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804353 CMS
Merck Sharp & Dohme Corporation $59.7406/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804355 CMS
Merck Sharp & Dohme Corporation $45.0006/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695806747 CMS
Merck Sharp & Dohme Corporation $147.3506/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804217 CMS
Merck Sharp & Dohme Corporation $237.1806/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804219 CMS
Merck Sharp & Dohme Corporation $783.0106/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804357 CMS
Merck Sharp & Dohme Corporation $120.0006/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695806745 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,777.27 8
PY2020 $2,500.00 2
PY2021 $7,900.36 5
PY2022 $1,125.00 1
PY2023 $1,125.00 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $13,296.00 3
PY2023 Recipient $3,200.00 1
PY2023 Principal investigator $192,152.84 3
PY2022 Recipient $330.00 1
PY2022 Principal investigator $406,381.59 42
PY2021 Recipient $4,000.00 1
PY2021 Principal investigator $395,644.11 30
PY2020 Principal investigator $261,247.84 61
PY2019 Principal investigator $566,446.06 129

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

129 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $452.00 12/31/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691503475
Principal investigator 1 Merck Sharp & Dohme Corporation $23,319.60 12/18/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691503627
Principal investigator 1 Merck Sharp & Dohme Corporation $15,500.45 12/12/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691503469
Principal investigator 1 Pacira Pharmaceuticals Incorporated $19,897.60 12/09/2019 Non-covered Recipient Entity
STANFORD UNIVERSITY MEDICAL CENTER
A MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF EXPAREL FOR POSTSURGICAL ANALGESIA IN PEDIATRIC SUBJECTS AGED 6 TO LESS THAN 17 YEARS. No dispute reported 06/30/2026 693062195
Principal investigator 1 Pacira Pharmaceuticals Incorporated $14,067.20 12/09/2019 Non-covered Recipient Entity
STANFORD UNIVERSITY MEDICAL CENTER
A MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF EXPAREL FOR POSTSURGICAL ANALGESIA IN PEDIATRIC SUBJECTS AGED 6 TO LESS THAN 17 YEARS. No dispute reported 06/30/2026 693062197
Principal investigator 1 Pacira Pharmaceuticals Incorporated $14,067.20 12/09/2019 Non-covered Recipient Entity
STANFORD UNIVERSITY MEDICAL CENTER
A MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF EXPAREL FOR POSTSURGICAL ANALGESIA IN PEDIATRIC SUBJECTS AGED 6 TO LESS THAN 17 YEARS. No dispute reported 06/30/2026 693062199
Principal investigator 1 Pacira Pharmaceuticals Incorporated $14,067.20 12/09/2019 Non-covered Recipient Entity
STANFORD UNIVERSITY MEDICAL CENTER
A MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF EXPAREL FOR POSTSURGICAL ANALGESIA IN PEDIATRIC SUBJECTS AGED 6 TO LESS THAN 17 YEARS. No dispute reported 06/30/2026 693062201
Principal investigator 1 Pacira Pharmaceuticals Incorporated $28,134.40 12/09/2019 Non-covered Recipient Entity
STANFORD UNIVERSITY MEDICAL CENTER
A MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF EXPAREL FOR POSTSURGICAL ANALGESIA IN PEDIATRIC SUBJECTS AGED 6 TO LESS THAN 17 YEARS. No dispute reported 06/30/2026 693062203
Principal investigator 1 Masimo Corporation $655.00 12/04/2019 Non-covered Recipient Entity
STANFORD UNIVERSITY
Hammer Stanford SpO2 No dispute reported 06/30/2026 700030203
Principal investigator 1 Merck Sharp & Dohme Corporation $452.00 12/03/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691503471
Principal investigator 1 Merck Sharp & Dohme Corporation $260.76 11/22/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691516609
Principal investigator 1 Merck Sharp & Dohme Corporation $45,827.65 11/19/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691447569
Principal investigator 1 Merck Sharp & Dohme Corporation $9,149.00 11/18/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691503631
Principal investigator 1 Merck Sharp & Dohme Corporation $3,019.50 11/14/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691447557
Principal investigator 1 Merck Sharp & Dohme Corporation $123.67 11/12/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691526535
Principal investigator 1 Merck Sharp & Dohme Corporation $134.68 11/12/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691526539
Principal investigator 1 Merck Sharp & Dohme Corporation $391.14 11/12/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691529225
Principal investigator 1 Merck Sharp & Dohme Corporation $59.40 11/08/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691519401
Principal investigator 1 Merck Sharp & Dohme Corporation $1.30 11/08/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691525594
Principal investigator 1 Merck Sharp & Dohme Corporation $2.30 11/08/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691525597
Principal investigator 1 Merck Sharp & Dohme Corporation $99.00 11/08/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691525601
Principal investigator 1 Merck Sharp & Dohme Corporation $1.44 11/08/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691533193
Principal investigator 1 Merck Sharp & Dohme Corporation $2.28 11/08/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691534721
Principal investigator 1 Merck Sharp & Dohme Corporation $34.92 11/08/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691534723
Principal investigator 1 Merck Sharp & Dohme Corporation $4.08 11/08/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691534725
Principal investigator 1 Merck Sharp & Dohme Corporation $7.92 11/08/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691534727
Principal investigator 1 Merck Sharp & Dohme Corporation $70.32 11/08/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691534903
Principal investigator 1 Merck Sharp & Dohme Corporation $72.60 11/08/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691534905
Principal investigator 1 Merck Sharp & Dohme Corporation $452.00 11/05/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691447561
Principal investigator 1 Merck Sharp & Dohme Corporation $452.00 11/05/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691447565
Principal investigator 1 Merck Sharp & Dohme Corporation $9,524.00 10/25/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691508595
Principal investigator 1 Merck Sharp & Dohme Corporation $42,885.75 10/17/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691337511
Principal investigator 1 Merck Sharp & Dohme Corporation $452.00 10/17/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691337515
Principal investigator 1 Merck Sharp & Dohme Corporation $452.00 10/17/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691337585
Principal investigator 1 Masimo Corporation $4,680.00 10/14/2019 Non-covered Recipient Entity
STANFORD UNIVERSITY
Hammer Stanford SpO2 No dispute reported 06/30/2026 700030197
Principal investigator 1 Merck Sharp & Dohme Corporation $1.26 10/03/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691395939
Principal investigator 1 Merck Sharp & Dohme Corporation $1.26 10/03/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691501775
Principal investigator 1 Merck Sharp & Dohme Corporation $12,326.75 09/26/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691345981
Principal investigator 1 Merck Sharp & Dohme Corporation $18,904.00 09/19/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691347017
Principal investigator 1 Merck Sharp & Dohme Corporation $452.00 09/19/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691347023
Principal investigator 1 Merck Sharp & Dohme Corporation $452.00 09/19/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691347025
Principal investigator 1 Masimo Corporation $4,680.00 09/18/2019 Non-covered Recipient Entity
STANFORD UNIVERSITY
Hammer Stanford SpO2 No dispute reported 06/30/2026 700030189
Principal investigator 1 Merck Sharp & Dohme Corporation $260.76 09/17/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691432863
Principal investigator 1 Merck Sharp & Dohme Corporation $189.72 09/12/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691436403
Principal investigator 1 Merck Sharp & Dohme Corporation $494.68 09/12/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691453479
Principal investigator 1 Merck Sharp & Dohme Corporation $28,572.00 09/11/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691420631
Principal investigator 1 Masimo Corporation $4,680.00 09/09/2019 Non-covered Recipient Entity
STANFORD UNIVERSITY
Hammer Stanford SpO2 No dispute reported 06/30/2026 700030179
Principal investigator 1 Masimo Corporation $4,680.00 09/09/2019 Non-covered Recipient Entity
STANFORD UNIVERSITY
Hammer Stanford SpO2 No dispute reported 06/30/2026 700030359
Principal investigator 1 Masimo Corporation $4,680.00 09/09/2019 Non-covered Recipient Entity
STANFORD UNIVERSITY
Hammer Stanford SpO2 No dispute reported 06/30/2026 700030363
Principal investigator 1 Masimo Corporation $4,680.00 09/09/2019 Non-covered Recipient Entity
STANFORD UNIVERSITY
Hammer Stanford SpO2 No dispute reported 06/30/2026 700030369
Principal investigator 1 Hikma Pharmaceuticals USA $38,141.90 08/16/2019 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Morphine Pediatric Study No dispute reported 06/30/2026 641062129
Principal investigator 1 Merck Sharp & Dohme Corporation $500.00 08/15/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691347031
Principal investigator 1 Merck Sharp & Dohme Corporation $9,232.00 08/15/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691347103
Principal investigator 1 Merck Sharp & Dohme Corporation $17.40 08/14/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691332871
Principal investigator 1 Merck Sharp & Dohme Corporation $6.99 08/14/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691352977
Principal investigator 1 Merck Sharp & Dohme Corporation $49.50 08/08/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691431555
Principal investigator 1 Merck Sharp & Dohme Corporation $0.65 08/08/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691443897
Principal investigator 1 Merck Sharp & Dohme Corporation $1.15 08/08/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691443967
Principal investigator 1 Masimo Corporation $159.35 08/07/2019 Non-covered Recipient Entity
STANFORD UNIVERSITY
Hammer Stanford SpO2 No dispute reported 06/30/2026 700030311
Principal investigator 1 Merck Sharp & Dohme Corporation $6.99 08/01/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691332873
Principal investigator 1 Merck Sharp & Dohme Corporation $195.57 07/26/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691432859
Principal investigator 1 Merck Sharp & Dohme Corporation $521.52 07/25/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691432867
Principal investigator 1 Merck Sharp & Dohme Corporation $9,524.00 07/19/2019 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 709106701
Principal investigator 1 Pacira Pharmaceuticals Incorporated $1,670.90 07/18/2019 Non-covered Recipient Entity
STANFORD UNIVERSITY
A MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF EXPAREL FOR POSTSURGICAL ANALGESIA IN PEDIATRIC SUBJECTS AGED 6 TO LESS THAN 17 YEARS. No dispute reported 06/30/2026 708146933
Principal investigator 1 Hikma Pharmaceuticals USA $5,915.00 07/12/2019 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Morphine Pediatric Study No dispute reported 06/30/2026 641062125
Principal investigator 1 Merck Sharp & Dohme Corporation $1.24 07/10/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691392043
Principal investigator 1 Merck Sharp & Dohme Corporation $0.23 07/10/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691392549
Principal investigator 1 Merck Sharp & Dohme Corporation $0.11 07/10/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691392715
Principal investigator 1 Merck Sharp & Dohme Corporation $0.12 07/10/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691392719
Principal investigator 1 Merck Sharp & Dohme Corporation $5.28 07/10/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691393571
Principal investigator 1 Merck Sharp & Dohme Corporation $0.26 07/10/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691394575
Principal investigator 1 Merck Sharp & Dohme Corporation $3.40 07/10/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691394767
Principal investigator 1 Merck Sharp & Dohme Corporation $9.90 07/10/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691394937
Principal investigator 1 Merck Sharp & Dohme Corporation $3.80 07/10/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691395127
Principal investigator 1 Merck Sharp & Dohme Corporation $30.92 07/10/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691395281
Principal investigator 1 Merck Sharp & Dohme Corporation $35.16 07/10/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691395283
Principal investigator 1 Merck Sharp & Dohme Corporation $4.14 07/10/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691395285
Principal investigator 1 Merck Sharp & Dohme Corporation $48.40 07/10/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691395289
Principal investigator 1 Merck Sharp & Dohme Corporation $1.90 07/10/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691395875
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 07/10/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691395879
Principal investigator 1 Merck Sharp & Dohme Corporation $20.26 07/10/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691395881
Principal investigator 1 Merck Sharp & Dohme Corporation $23.28 07/10/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691395885
Principal investigator 1 Merck Sharp & Dohme Corporation $0.12 07/10/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691396889
Principal investigator 1 Merck Sharp & Dohme Corporation $15.75 07/10/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691397023
Principal investigator 1 Merck Sharp & Dohme Corporation $39.60 07/10/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691397361
Principal investigator 1 Merck Sharp & Dohme Corporation $144.60 07/08/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691342291
Principal investigator 1 Hikma Pharmaceuticals USA $4,743.80 07/01/2019 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Morphine Pediatric Study No dispute reported 06/30/2026 641062119
Principal investigator 1 Merck Sharp & Dohme Corporation $750.00 06/21/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691368505
Principal investigator 1 Merck Sharp & Dohme Corporation $144.60 06/19/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616 for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to 2 Years No dispute reported 06/30/2026 691342453
Principal investigator 1 Pacira Pharmaceuticals Incorporated $18,048.00 06/19/2019 Non-covered Recipient Entity
STANFORD UNIVERSITY MEDICAL CENTER
A MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF EXPAREL FOR POSTSURGICAL ANALGESIA IN PEDIATRIC SUBJECTS AGED 6 TO LESS THAN 17 YEARS. No dispute reported 06/30/2026 693062085
Principal investigator 1 Merck Sharp & Dohme Corporation $3,727.50 06/12/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691368497
Principal investigator 1 Merck Sharp & Dohme Corporation $525.00 06/12/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691368501
Principal investigator 1 Pacira Pharmaceuticals Incorporated $1,670.90 06/05/2019 Non-covered Recipient Entity
STANFORD UNIVERSITY
A MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF EXPAREL FOR POSTSURGICAL ANALGESIA IN PEDIATRIC SUBJECTS AGED 6 TO LESS THAN 17 YEARS. No dispute reported 06/30/2026 708146907
Principal investigator 1 Hikma Pharmaceuticals USA $54,654.10 06/04/2019 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Morphine Pediatric Study No dispute reported 06/30/2026 641062007
Principal investigator 1 Merck Sharp & Dohme Corporation $27,822.00 05/23/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691322387
Principal investigator 1 Masimo Corporation $2,600.00 05/22/2019 Non-covered Recipient Entity
STANFORD UNIVERSITY
Hammer Stanford SedLine Eng. Data Collection No dispute reported 06/30/2026 700030019
Principal investigator 1 Hikma Pharmaceuticals USA $6,485.00 05/10/2019 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Morphine Pediatric Study No dispute reported 06/30/2026 641062003
Principal investigator 1 Hikma Pharmaceuticals USA $17,507.50 05/06/2019 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Morphine Pediatric Study No dispute reported 06/30/2026 641061997
Principal investigator 1 Merck Sharp & Dohme Corporation $195.57 04/27/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691432855
Principal investigator 1 Merck Sharp & Dohme Corporation $17.40 04/26/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691342293
Principal investigator 1 Merck Sharp & Dohme Corporation $24.20 04/08/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691377651
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 04/08/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691378221
Principal investigator 1 Merck Sharp & Dohme Corporation $30.92 04/08/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691394653
Principal investigator 1 Merck Sharp & Dohme Corporation $35.16 04/08/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691394655
Principal investigator 1 Merck Sharp & Dohme Corporation $118.80 04/08/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691395223
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 04/08/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691395227
Principal investigator 1 Merck Sharp & Dohme Corporation $12.24 04/08/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691395749
Principal investigator 1 Merck Sharp & Dohme Corporation $19.80 04/08/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691395753
Principal investigator 1 Merck Sharp & Dohme Corporation $2.08 04/08/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691395757
Principal investigator 1 Merck Sharp & Dohme Corporation $20.26 04/08/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691395761
Principal investigator 1 Merck Sharp & Dohme Corporation $3.08 04/08/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691395765
Principal investigator 1 Merck Sharp & Dohme Corporation $3.80 04/08/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691395849
Principal investigator 1 Merck Sharp & Dohme Corporation $4.14 04/08/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691395931
Principal investigator 1 Merck Sharp & Dohme Corporation $6.84 04/08/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691395935
Principal investigator 1 Pacira Pharmaceuticals Incorporated $1,670.90 04/04/2019 Non-covered Recipient Entity
STANFORD UNIVERSITY
A MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF EXPAREL FOR POSTSURGICAL ANALGESIA IN PEDIATRIC SUBJECTS AGED 6 TO LESS THAN 17 YEARS. No dispute reported 06/30/2026 708146895
Principal investigator 1 Merck Sharp & Dohme Corporation $5,000.00 03/29/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691322391
Principal investigator 1 Hikma Pharmaceuticals USA $3,501.50 03/28/2019 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Morphine Pediatric Study No dispute reported 06/30/2026 641062025
Principal investigator 1 Merck Sharp & Dohme Corporation $7,200.00 03/27/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691322291
Principal investigator 1 Hikma Pharmaceuticals USA $256.00 03/01/2019 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Morphine Pediatric Study No dispute reported 06/30/2026 641062019
Principal investigator 1 Merck Sharp & Dohme Corporation $75.49 02/26/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex MK-8616for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691342731
Principal investigator 1 Merck Sharp & Dohme Corporation $465.26 02/21/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616)for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691287941
Principal investigator 1 Merck Sharp & Dohme Corporation $137.58 02/14/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616)for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691287859
Principal investigator 1 Merck Sharp & Dohme Corporation $494.68 02/14/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616)for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691287945
Principal investigator 1 Merck Sharp & Dohme Corporation $758.88 02/14/2019 Covered Recipient Teaching Hospital
LUCILE PACKARD CHILDRENS HOSPITAL
A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616)for Reversal of Neuromuscular Blockade in Pediatric Participants No dispute reported 06/30/2026 691287949
Principal investigator 1 Masimo Corporation $655.00 01/31/2019 Non-covered Recipient Entity
STANFORD UNIVERSITY
Hammer Stanford SedLine Eng. Data Collection No dispute reported 06/30/2026 700029952
Principal investigator 1 Masimo Corporation $655.00 01/28/2019 Non-covered Recipient Entity
STANFORD UNIVERSITY
Hammer Stanford SpO2 No dispute reported 06/30/2026 700029941
Principal investigator 1 Masimo Corporation $4,680.00 01/28/2019 Non-covered Recipient Entity
STANFORD UNIVERSITY
Hammer Stanford SpO2 No dispute reported 06/30/2026 700029947
Principal investigator 1 Hikma Pharmaceuticals USA $220.00 01/17/2019 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Morphine Pediatric Study No dispute reported 06/30/2026 641062015
Principal investigator 1 Hikma Pharmaceuticals USA $1,308.60 01/04/2019 Non-covered Recipient Entity
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Morphine Pediatric Study No dispute reported 06/30/2026 641062012